Terapia empírica con I-131: ¿sigue vigente?

Autores/as

  • Felipe Fierro Instituto Nacional de Cancerología

Biografía del autor/a

Felipe Fierro, Instituto Nacional de Cancerología

Servicio de Endocrinología, Instituto Nacional de Cancerología, Bogotá, D.C. Colombia

Referencias bibliográficas

Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164- 7.

https://doi.org/10.1001/jama.295.18.2164

Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114(6):1050-7; discussion 1057-8.

Garavito G. Factores pronósticos para la recaída en pacientes con cáncer papilar de tiroides /Prognostic factors related with recurrence in papillary thyroid cancer. Rev Colomb Cancerol. 2005;9(2):21-30.

Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med. 1999;26(11):1448-52.

https://doi.org/10.1007/s002590050477

Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a metaanalysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97(8):2754-63.

https://doi.org/10.1210/jc.2012-1533

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674-85.

https://doi.org/10.1056/NEJMoa1109589

Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663-73.

https://doi.org/10.1056/NEJMoa1108586

Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the Initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341-9.

https://doi.org/10.1089/thy.2010.0178

Perros P, Boelaert K, Colley S, Evans C, Evans R, Gerrard G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol Clin J Soc Endocrinol Endocr Soc Aust. 2014;81:1-276.

https://doi.org/10.1111/cen.12515

Schlumberger M. Papillary follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297-306.

https://doi.org/10.1056/NEJM199801293380506

Cooper DS, Doherty GM, Haugen BR, Mazzaferri EL, Mciver B, Pacini F, et al. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.

https://doi.org/10.1089/thy.2009.0110

Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7(2):273-6.

https://doi.org/10.1089/thy.1997.7.273

Reynolds JC. Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. Thyroid. 1997;7(2):281-4.

https://doi.org/10.1089/thy.1997.7.281

Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(8):3668-73.

https://doi.org/10.1210/jc.2002-021925

Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab. 2014. Feb;99(2):440-7.

https://doi.org/10.1210/jc.2013-3156

Mazzaferri E. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46(7):1079-88.

Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: Comparison of patients treated with high 131I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86(9):4092-7.

https://doi.org/10.1210/jcem.86.9.7831

Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2007;66(1):58-64.

Cómo citar

[1]
Fierro, .F. 2014. Terapia empírica con I-131: ¿sigue vigente?. Revista Colombiana de Cancerología. 18, 4 (dic. 2014), 155–156.

Descargas

Los datos de descargas todavía no están disponibles.

Descargas

Publicado

01-12-2014

Número

Sección

Editorial